Feasibility of intravitreal erythropoietin injections in humans

British Journal of Ophthalmology

Volumn 93, Issue 12, 2009, Pages 1667-1671

  Lagreze W A ^a   Feltgen, N ^a   Bach, M ^a   Jehle, T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYPO FS; ERYTHROPOIETIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CASE REPORT; ELECTRORETINOGRAM; FEASIBILITY STUDY; FEMALE; HEMATOCRIT; HUMAN; INTRAOCULAR PRESSURE; MALE; NEUROPATHY; NON ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; OBSERVATION; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA ARTERY OCCLUSION; VISUAL ACUITY; VISUAL FIELD;

AGED; ELECTRORETINOGRAPHY; EPOETIN ALFA; ERYTHROPOIETIN; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; OPTIC NEUROPATHY, ISCHEMIC; PILOT PROJECTS; RETINAL ARTERY OCCLUSION; VISUAL ACUITY; VISUAL FIELDS; VITREOUS BODY;

EID: 72449182177     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.156794     Document Type: Article

References (26)

1. Lagrèze WA. Neuroprotection. Bases and possibilities of a future clinical use. Ophthalmologe 2001;98:235-236
2. Ehrenreich H, Fischer B, Norra C, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130:2577-2588 (Pubitemid 47511714)
3. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591
4. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
5. Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834-1839.
6. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95:4635-4640
7. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531 (Pubitemid 30707300)
8. Kretz A, Happold CJ, Marticke JK, et al. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell Neurosci 2005;29:569-579 (Pubitemid 40984698)
9. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-583
10. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242
11. Weishaupt JH, Rohde G, Polking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:1514-1522 (Pubitemid 38859333)
12. Diem R, Sattler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005;128:375-385 (Pubitemid 40222606)
13. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007;48:1212-1218 (Pubitemid 351261416)
14. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci 2008;49:732-742
15. King CE, Rodger J, Bartlett C, et al. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007;205:48-55. (Pubitemid 46617489)
16. Ischemic Optic Neuropathy Decompression Trial Research Group. Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol 2000;118:793-798
17. Atebara NH, Brown GC, Cater J. Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology 1995;102:2029-34; discussion 34-35
18. Fraser S, Siriwardena D. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev 2002;(1):CD001989.
19. Buono LM, Foroozan R, Sergott RC, et al. Nonarteritic anterior ischaemic optic neuropathy. Curr Opin Ophthalmol 2002;13:357-361 (Pubitemid 35397643)
20. Fu QL, Wu W, Wang H, et al. Up-regulated endogenous erythropoietin/ erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol 2008;28:317-329
21. Inomata Y, Hirata A, Takahashi E, et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 2004;15:877-879 (Pubitemid 38453478)
22. Garci-Arumi J, Fonollosa A, Macia C, et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema. Eye 2009;23:1066-1071
23. Asensio-Sanchez VM, Gomez-Ramirez V, Morales-Gomez I. Erythropoietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy. Arch Soc Esp Oftalmol 2008;83:169-172
24. Dureau P, Bonnel S, Menasche M, et al. Quantitative analysis of intravitreal injections in the rat. Curr Eye Res 2001;22:74-77 (Pubitemid 32680906)
25. Zhang JF, Wu YL, Xu JY, et al. Pharmacokinetic and toxicity study of intravitreal erythropoietin in rabbits. Acta Pharmacol Sinica 2008;29:1383-1390
26. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811